

Supplementary references

- S1. Cavalier E, Delanaye P, Vranken L et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. *Nephrol Dial Transplant*. 2012;27:1950-1956.
- S2. Evenepoel P, Jørgensen HS, Komaba H et al. Lower Bone Turnover and Skeletal PTH Responsiveness in Japanese Compared to European Patients on Hemodialysis. *J Clin Endocrinol Metab*. 2022;107:e4350-e4359.
- S3. Pisoni RL, Bragg-Gresham JL, Young EW et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Am J Kidney Dis*. 2004; 44: 94–111
- S4. Goodkin DA, Young EW, Kurokawa K et al. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. *Am J Kidney Dis*. 2004;44:16-21.
- S5. Yamamoto S, Jørgensen HS, Zhao J et al. Alkaline Phosphatase and Parathyroid Hormone Levels: International Variation and Associations With Clinical Outcomes in the DOPPS. *Kidney Int Rep*. 2024;9:863-876.
- S6. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. *Am J Kidney Dis*. 2000;36:1115-1121.
- S7. Danese MD, Kim J, Doan QV et al. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. *Am J Kidney Dis*. 2006;47:149-156.
- S8. Jadoul M, Albert JM, Akiba T et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. *Kidney Int*. 2006;70:1358-1366.
- S9. Ketteler M, Block GA, Evenepoel P et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. *Kidney Int*. 2017;92:26-36.